TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213

IQVIA Holdings Inc. (NYSE:IQV) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213

On March 9, 2026, TD Cowen upgraded its rating on IQVIA Holdings Inc. (NYSE:IQV) from Hold to Buy. Along with the rating upgrade, the firm also raised its price target on the stock from $174 to $213. The company is anticipated to remain resilient against AI-driven revenue headwinds, according to TD Cowen analysts. It further noted that AI could potentially reduce drug trial costs by 10% to 15%, but these savings are expected to be further reinvested into research activity. Following a 24% share price decline since February, TD Cowen sees an attractive risk-reward opportunity.

Prior to this, in an unrelated event, Barclays also upgraded IQVIA Holdings Inc. (NYSE:IQV)’s rating from Equal Weight to Overweight, while maintaining a price target of $210. The firm’s analyst anticipates an upside for the stock, projecting higher valuations and financial estimates. It added in a research note that the consistency in its execution justifies a premium market valuation for IQVIA Holdings Inc. (NYSE:IQV).

Founded in 1982, IQVIA Holdings Inc. (NYSE:IQV) is a global leader in clinical research and health data, headquartered in North Carolina.

While we acknowledge the risk and potential of IQV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IQV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.